Senda Biosciences

📍 Cambridge, United States🗓 Founded 2017👥 94 employees💰 Last funded Sep 2019
Senda Biosciences, Inc. is uniquely positioned to transform human health by harnessing millions of years of evolution to program targeted, potent and tunable medicines. Nature has provided the codes to program human cells – both within the cell (mRNA), and, remarkably, to the cell - using what surrounds it. The trillions of non-human cells in the human ecosystem have evolved natural nanoparticles that precisely shuttle biomolecules into human cells, providing the missing pieces to fully unlock programmable medicines. Senda’s proprietary platform includes the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life – accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines. The unique properties of these medicines create new frontiers for mRNA therapeutics and vaccines for infectious, genetic, autoimmune, and metabolic diseases and oncology indications – with further potential to transform the gene editing and protein-based therapy landscapes as well. Based in Cambridge, MA, Senda was founded by Flagship Pioneering.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2017
Founded
Investor geography1 country
United States
3
Investor activity2017–2019 · investors recorded per year
2017120192
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Senda Biosciences?
Senda Biosciences has 3 investors on record on gritt.io, including 3 early-stage backers.
When did Senda Biosciences last raise funding?
The most recent investment in Senda Biosciences recorded on gritt.io was in September 2019.
When was Senda Biosciences founded?
Senda Biosciences was founded in 2017.
What industry is Senda Biosciences in?
Senda Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Senda Biosciences based?
Senda Biosciences is headquartered in Cambridge, United States.